Triple-Hormone Therapy Shows Strong Results for Type 2 Diabetes and Obesity

AI-generated NewsSnap summary based on source reporting.
Published: 2026-06-08
Category: health
Source: BioSpace (citing The Lancet and American Diabetes Association)
Original source

New Phase 3 trial data for retatrutide, a pioneering triple-hormone receptor agonist, indicate significant improvements in type 2 diabetes and obesity. The drug demonstrated substantial glucose control and an average weight loss of over 16% in adults, while also improving cardiovascular risk factors. Its safety profile was comparable to existing GLP-1 receptor agonists.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai